Should older men be screened for prostate cancer?

May 02, 2006

Screening for prostate cancer in older men has been problematic. While this form of cancer can be fatal, it often progresses so slowly that men are more likely to die from some other disease. Aggressive treatments such as radical prostatectomy or radiation therapy may eradicate the cancer but have negative effects on quality of life. More conservative treatments may preserve quality of life, but may not be appropriate for those cases where the disease is progressing more quickly. In the face of these uncertainties, what is the appropriate age to stop screening?

Although guidelines suggest that men 75 years or older may not benefit from screening, surveys continue to show high rates of screening in this population. Since most screening and treatment trials for prostate cancer have systematically excluded older men, there are no well-characterized data about survival and quality-of-life issues.

In a population-based cohort study published in the May issue of The American Journal of Medicine, researchers followed 465 men aged 75 to 84 who had been diagnosed with clinically localized prostate cancer in 1994 or 1995. Of those patients, 175 received aggressive treatment (surgery or radiation therapy) and 290 received hormone therapy or no treatment. The authors evaluated health-related quality of life (HRQOL) outcomes and survival 2 years after the original diagnosis. Survival was also evaluated 7 years after diagnosis.

Writing in the article, Richard M. Hoffman, MD, MPH, of the Medicine Service, New Mexico VA Health Care System and the University of New Mexico Cancer Research and Treatment Center, concludes, "Aggressive treatment minimally reduced the risk of dying from prostate cancer; disease specific survival, however, was relatively high in both groups because most deaths were from other causes. However, by 24 months following diagnosis, men who received aggressive treatment had suffered more urinary and bowel dysfunction and were more bothered by sexual dysfunction. General health and physical function were higher for aggressively treated men but this was likely due to residual selection bias. Our results reinforce concerns that men 75 years and older may not benefit from prostate cancer screening because they may suffer adverse outcomes from aggressive treatment of localized disease."
-end-
The article, "Health Outcomes in Older Men with Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study" by Richard M. Hoffman, MD, MPH, Michael J. Barry, MD, Janet L. Stanford, PhD, Ann S. Hamilton, PhD, William C. Hunt, MS, and Mary McNaughton Collins, MD, MPH, appears in The American Journal of Medicine, Volume 119, Number 5 (May 2006), published by Elsevier.

Elsevier

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.